Pricing Options

Please select your ticket type depending on whether or not you require CE/CME.

  • Program with NYSED CE for LMHC, Social Workers, and Psychologists: $525

  • Program with CE for Psychologists (APA), Nurses (ANCC), and Social Workers not based in NY (ASWB): $590

  • Program with ACCME for Physicians: $795

  • $525.00

    Program Ticket with NYSED CE for LMHC, Social Workers, and Psychologists

    Register Now
To obtain your certificate, the CE/CME forms must be filled out within 14 days of class completion. Please see all additional CE/CME info below.

Program Description

Live-Online Webinar 10AM - 3PM EDT, May 6, 7, & 8, 2022

  • Psychedelic compounds have a rich and fascinating history of use in spiritual and healthcare settings. After a nearly 60-year hiatus, recent advances in clinical research indicate that these medicines may soon be available to the public as treatments for some of humanity’s most profound forms of suffering: alcoholism, drug addiction, PTSD, and depression. Psychotherapists and other healthcare providers are increasingly called upon to help clients integrate profoundly meaningful psychedelic experiences into the fabric of their daily lives, resulting in long-term positive changes.

  • This 3-day training is designed for clinicians and healthcare providers who want to learn more about current psychedelic research and clinical practice, including how to work with patients who have a history of psychedelic use or have expressed an interest in using psychedelics. This interactive training includes experiential learning, demonstrations, self-reflection, and role-play exercises. The themes of spirituality, ethics, and critical discussion will be woven throughout the program with opportunities for connection, collaboration, and building community.

  • We start with the premise that your patients are curious about psychedelic research, and so are you! The early part of our program gives some background on psychedelic compounds, their history, and current research with MDMA and Psilocybin-assisted therapy. We then discuss recent and current clinical trials, outcomes, legal status, and what it all means for the future of addiction and trauma treatment. We then move to the practicalities of defining integration and how it can occur in a clinical setting. We focus on translating research findings into clinical practice, including working with patients who are considering using psychedelics, actually using psychedelics, or have used them in the past.

  • This program includes discussion of assessment and integration techniques, resources, and legal and ethical issues. Program participant clinicians will complete the retreat with a conceptual and practical understanding of how to engage clients in discussions about psychedelics that are balanced, reduce potential for harm, and increase the potential for benefit from these experiences.

Learning Objectives

  • Discuss the historical justifications for psychedelic clinical research

  • Describe key theoretical approaches to psychedelic-assisted therapy

  • Discuss the state of psychedelic clinical research, rescheduling efforts, and how psychedelic-assisted psychotherapy works with clients

  • Compare psychedelic integration psychotherapy to integration in peer and shamanic settings

  • Assess clients for key “red flags” that indicate someone should seek specialized psychiatric care after a psychedelic experience

  • Utilize principles of psychedelic-assisted therapy in a basic/initial assessment of clients who report psychedelic use

  • List contraindications and discuss high risk cases of individuals who are contemplating psychedelic use

  • Describe the role of the therapist in an individual's integration psychotherapy process

Resources

Registration includes access to our online classroom, course handouts, and private course discussion board. All attendees may opt to be added to our professional community email list of over 600 professionals who have completed this (or similar) courses with us.

Certificate Program

This course can be taken in partial fulfillment of the requirements for the Postgraduate Certificate in Psychedelic Integration Therapy.
Click Here to Learn More

Instructors

Chief Executive Officer, Co-Founder and Trainer

Ingmar Gorman, PhD

Dr. Ingmar Gorman is a psychologist who specializes in helping people who use psychedelics and other psychoactive compounds. He received his clinical training at the New School for Social Research, Mount Sinai Beth Israel Hospital, Columbia University, and Bellevue Hospital. He completed his NIH postdoctoral fellowship at New York University in 2017. Dr. Gorman was formerly the Director of the Psychedelic Education and Continuing Care Program at the Center for Optimal Living and is now the co-founder of Fluence, a psychedelic education company training mental health providers in psychedelic treatments. Along with Dr. Paleos, he is currently site co-principal investigator and therapist on a Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder.

Chief Visionary Officer, Co-Founder and Trainer

Elizabeth Nielson, PhD

Dr. Elizabeth Nielson is a co-founder of Fluence and a psychologist with a focus on developing psychedelic medicines as empirically supported treatments for PTSD, substance use problems, and mood disorders. Dr. Nielson is a therapist on FDA approved clinical trials of psilocybin-assisted treatment of alcohol use disorder, MDMA-assisted treatment PTSD, and psilocybin-assisted treatment of treatment resistant depression. Through Fluence, she provides continuing education and training programs for therapists who wish to engage in integration of psychedelic experiences in clinical settings. Her program of research includes qualitative and mixed-methods projects designed to further understand the phenomenology and mechanisms of change in psychedelic-assisted therapy, including the experiences of trial participants and of the therapists themselves. Having completed an NIH postdoctoral fellowship at NYU, she has published and presented on topics of psychedelic therapist training, therapists’ personal experience with psychedelics, and including psychedelic integration in group and individual psychotherapy.

Psychoanalytic Program Director and Trainer

Jeffrey Guss, MD

Jeffrey Guss, MD is a psychiatrist, psychoanalyst, and researcher with specializations in psychoanalytic therapy, addictions and psychedelic therapy. He was Co-Principal Investigator and Director of Psychedelic Therapy Training for the NYU School of Medicine’s study on psilocybin-assisted psychotherapy in the treatment of cancer related existential distress, which was published in Journal of Psychopharmacology, 2016. He currently is a study therapist in the NYU study on Psilocybin-Assisted treatment of Major Depressive Disorder, a collaborator with Yale University’s study on psilocybin-assisted therapy for Major Depressive Disorder and a study therapist with the MAPS study on treatment of Post Traumatic Stress Disorder with MDMA-Assisted Psychotherapy. Jeff is interested in the integration of psychedelic therapies with contemporary psychoanalytic theory and has published in Studies in Gender and Sexuality and Psychoanalysis, Culture and Society. He co-authored a paper on the influence of therapists’ first hand experience with psychedelics on psychedelic-assisted psychotherapy research in The Journal of Psychedelic Studies. He is an Instructor and Mentor with the California Institute of Integral Studies’ Center for Psychedelic Therapies. He maintains a private practice in New York City.

Psychedelic Harm Reduction and Integration Certificate Program Director and Trainer

Alexander Camargo, PsyD

Dr. Alex Camargo is a psychologist based in New York City and maintains a private practice in Manhattan. His work is heavily influenced by psychoanalytic and attachment theories where he works with clients to address anxiety, depression, life transitions and spiritual crises. In addition, he provides psychedelic harm reduction and integration, helping clients prepare for psychedelic experiences, incorporate insights or cope with challenges post-experience. He has also been employed to be a study therapist on a clinical trial investigating the impact of psilocybin on the treatment of body dysmorphic disorder at New York Psychiatric Institute. Dr. Camargo’s clinical training focused on providing mental health services in low-fee clinics and hospitals to traditionally underserved communities the Bronx, Brooklyn, and Nassau County.

Continuing Education

Continuing Education Credits for Health Professionals (CE)

  • Fluence International, Inc. is approved by the American Psychological Association to sponsor continuing education for psychologists. Fluence maintains responsibility for this program and its content.

  • Fluence International, Inc. is recognized by the New York State Education Department’s State Board for Mental Health Practitioners as an approved provider of continuing education for licensed mental health counselors. #MHC-0232.

  • Fluence International, Inc. is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0674.

  • Fluence International, Inc. is recognized by the New York State Education Department's State Board for Psychology as an approved provider of continuing education for licensed psychologists #PSY-0167.

  • The Department’s approval of a provider of continuing education does not constitute the Department’s endorsement of the content, positions or practices that may be addressed in any specific continuing education course offered by the approved provider.

  • For questions about receiving your CE/CME Certificate or Certificate of Attendance, contact Selah Drain, selah@fluencetraining.com.

Continuing Education (CE) and Continuing Medical Education (CME) for Medical Professionals

  • In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Fluence International, Inc. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

  • Amedco LLC designates this activity for a maximum of 13.50 ANCC contact hours.

  • Amedco LLC designates this live activity for a maximum of 13.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • As a Jointly Accredited Organization, Amedco is approved to offer social work continuing education by the Association of Social Work Boards(ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. Amedco maintains responsibility for this course. Social Workers completing this course receive 13.50 GENERAL continuing education credits.

  • ‍The following state boards accept courses offering ASWB ACE credit for Social Workers: AK, AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, HI, ID, IL, IN, IA, KS, KY,LA, ME, MD, MA, MI, MN, MS, MO, MT, NC, ND, NE, NH, NM, NV, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, VA, WA, WI, WV,WY

  • * WV accepts ASWB ACE unless activity is live in West Virginia, then an application is required.

  • The following state boards accept courses offering ASWB ACE credit for Counselors: AK, AR, AZ, CA, CO, CT, DC, FL, GA, IA, ID, IL, IN, KS, MA, MD,ME, MO, ND, NE, NM, NH, NV, OK, OR, PA, TN, TX, UT, VA, WI, WY

  • AL/Counselors: Activities not providing NBCC approval may be approved by the Board for individual licensees upon receipt of acceptable documentation prior to the activity. Please send course details to your licensing board for approval BEFORE the event. No approvals afterward by the board.

  • MI: No CE requirement

  • The following state boards accept courses offering ASWB ACE credit for MFTs: AK, AR, AZ, CA, CO, FL, IA, ID, IN, KS, MD, ME, MO, NC, NE, NH, NM, NV,OK, OR, PA, RI, TN, TX, UT, VA, WI, WY

  • MA / MFTs: Participants can self-submit courses not approved by the MAMFT board for review.

  • MI: No CE requirement

  • The following state boards accept courses offering ASWB ACE credit for Addictions Professionals: AK,CA, CO, CT, GA, IA, IN, KS, LA, MO, MT, ND, NM, NV, OK, OR, SC, WA, WI, WV, WY

  • Amedco is recognized by the New York State Education Department’s State Board for Psychology as an approved provider of continuing education for licensed psychologists #PSY-0031. 13.50 hours.

  • Fluence will issue a non-CE/CME Certificate of Attendance for all attendees who complete this program. For questions about receiving your Certificate of Attendance, contact Selah Drain, selah@fluencetraining.com.

Accreditation and Affiliation

American Association for Adult and Continuing Education